Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) -– By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global HPV Vaccine Market by End-User (Male and Female), By Age-Group (Adolescent and Adults), By Region (North America, Europe, Asia Pacific, Rest of the world) and By Country (U.S., Canada, United Kingdom, Germany, France, Japan China, India).
According to Azoth Analytics research report “Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) – By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)”, the global market is projected to display a robust growth represented by a CAGR of 4.18% during 2017 – 2022.
The segment of Female HPV vaccine market witnessed growth at a noteworthy rate over the past few years and is expected to grow in the forecast period on the back of rising awareness regarding HPV related fatal diseases, rising healthcare expenditures along with rising disposable incomes. Amongst the regions, North America accounts for the largest regional share in the global HPV vaccine market in 2017. Key factors driving the robust growth rate of North America region include emergence of second generation of HPV vaccines with lower dosage schedule and increasing HPV vaccination recommendation for male adolescents and adult population, increasing number of patients diagnosed with anogenital and oropharynx cancers as well as rising prevalence of HPV virus.
The report titled “Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) – By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)” has covered and analysed the potential of Global HPV Vaccine Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global HPV vaccine market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global HPV Vaccine Market (Actual Period: 2012-2016, Forecast Period: 2017-2022
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global HPV Vaccine Market by End-User (Male and Female), By Age-Group (Adolescent and Adults), By Region (North America, Europe, Asia Pacific, Rest of the world) and By Country (U.S., Canada, United Kingdom, Germany, France, Japan China, India).
According to Azoth Analytics research report “Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) – By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)”, the global market is projected to display a robust growth represented by a CAGR of 4.18% during 2017 – 2022.
The segment of Female HPV vaccine market witnessed growth at a noteworthy rate over the past few years and is expected to grow in the forecast period on the back of rising awareness regarding HPV related fatal diseases, rising healthcare expenditures along with rising disposable incomes. Amongst the regions, North America accounts for the largest regional share in the global HPV vaccine market in 2017. Key factors driving the robust growth rate of North America region include emergence of second generation of HPV vaccines with lower dosage schedule and increasing HPV vaccination recommendation for male adolescents and adult population, increasing number of patients diagnosed with anogenital and oropharynx cancers as well as rising prevalence of HPV virus.
The report titled “Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) – By Region (North America, Europe, APAC and RoW), By Country (US, Canada, UK, Germany, France, China, India, Japan)” has covered and analysed the potential of Global HPV Vaccine Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global HPV vaccine market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global HPV Vaccine Market (Actual Period: 2012-2016, Forecast Period: 2017-2022
- Global HPV Vaccine Market – Size and Growth
- By End User – Male and Female
- By Age Group – Adolescent and Adults
- HPV Vaccine Market – Size and Growth
- By End User – Male and Female
- By Age Group – Adolescent and Adults
- HPV vaccine Market – Size and Growth
- By End User – Male and Female
- Market Dynamics – Drivers and Restraints
- Market Trends
- Porter Five Force Analysis
- Policy and Regulatory Landscape
- Company Analysis – Merck and Co,, GlaxoSmithKline
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
4. HPV VACCINE MARKET: PRODUCT OUTLOOK
5. GLOBAL HPV VACCINE MARKET: GROWTH AND FORECAST
5.1. Global HPV Vaccine Market, By Value (2012-2016)
5.2. Global HPV Vaccine Market, By Value (2017-2022)
5.3. Global HPV Vaccine Market - By End-User, By Value
5.3.1. Global HPV Vaccine Market, By Value, % (2016)
5.3.2. Global HPV Vaccine Market, By Value, % (Forecast 2022F)
5.4. Global HPV Vaccine Market, By End-User, By Value (2012-2022)
5.4.1. Male, By Value (2012-2022)
5.4.2. Female, By Value (2012-2022)
5.5. Global HPV Vaccine Market, By Age-Group, By Value (2012-2022)
5.5.1. Adolescent, By Value (2012-2022)
5.5.2. Adult, By Value (2012-2022)
6. NORTH AMERICA HPV VACCINE MARKET: GROWTH AND FORECAST
6.1. North America HPV Vaccine Market, By Value (2012-2016)
6.2. North America HPV Vaccine Market, By Value (2017-2022)
6.3. North America HPV Vaccine Market - By End-User, By Value
6.3.1. North America HPV Vaccine Market, By Value, % (2016)
6.3.2. North America HPV Vaccine Market, By Value, % (Forecast 2022F)
6.4. North America HPV Vaccine Market, By End-User, By Value (2012-2022)
6.4.1. Male, By Value (2012-2022)
6.4.2. Female, By Value (2012-2022)
6.5. North America HPV Vaccine Market, By Age-Group, By Value (2012-2022)
6.5.1. Adolescent, By Value (2012-2022)
6.5.2. Adult, By Value (2012-2022)
6.6. North America HPV Vaccine Market: Country Analysis (U.S., Canada)
6.6.1. North America HPV Vaccine Market, Country Share, 2016 (% of Total)
6.6.2. North America HPV Vaccine Market, Country Share, 2022 (% of Total)
6.7. U.S. HPV Vaccine Market: Growth and Forecast
6.7.1. U.S. HPV Vaccine Market, By Value (2012-2016)
6.7.2. U.S. HPV Vaccine Market, By Value (2017-2022)
6.8. U.S. HPV Vaccine Market - By End-User, By Value
6.8.1. Male, By Value (2012-2022)
6.8.2. Female, By Value (2012-2022)
6.9. Canada HPV Vaccine Market: Growth and Forecast
6.9.1. Canada HPV Vaccine Market, By Value (2012-2016)
6.9.2. Canada HPV Vaccine Market, By Value (2017-2022)
6.10. Canada HPV Vaccine Market - By End-User, By Value
6.10.1. Male, By Value (2012-2022)
6.10.2. Female, By Value (2012-2022)
7. EUROPE HPV VACCINE MARKET: GROWTH AND FORECAST
7.1. Europe HPV Vaccine Market, By Value (2012-2016)
7.2. Europe HPV Vaccine Market, By Value (2017-2022)
7.3. Europe HPV Vaccine Market - By End-User, By Value
7.3.1. Europe HPV Vaccine Market, By Value, % (2016)
7.3.2. Europe HPV Vaccine Market, By Value, % (Forecast 2022F)
7.4. Europe HPV Vaccine Market, By End-User, By Value (2012-2022)
7.4.1. Male, By Value (2012-2022)
7.4.2. Female, By Value (2012-2022)
7.5. Europe HPV Vaccine Market, By Age-Group, By Value (2012-2022)
7.5.1. Adolescent, By Value (2012-2022)
7.5.2. Adult, By Value (2012-2022)
7.6. Europe HPV Vaccine Market: Country Analysis (U.K., Germany, France & Rest of Europe)
7.6.1. Europe HPV Vaccine Market, Country Share, 2016 (% of Total)
7.6.2. Europe HPV Vaccine Market, Country Share, 2022 (% of Total)
7.7. U.K. HPV Vaccine Market: Growth and Forecast
7.7.1. U.K. HPV Vaccine Market, By Value (2012-2016)
7.7.2. U.K. HPV Vaccine Market, By Value (2017-2022)
7.8. U.K. HPV Vaccine Market - By End-User, By Value
7.8.1. Male, By Value (2012-2022)
7.8.2. Female, By Value (2012-2022)
7.9. Germany HPV Vaccine Market: Growth and Forecast
7.9.1. Germany HPV Vaccine Market, By Value (2012-2016)
7.9.2. Germany HPV Vaccine Market, By Value (2017-2022)
7.10. Germany HPV Vaccine Market - By End-User, By Value
7.10.1. Male, By Value (2012-2022)
7.10.2. Female, By Value (2012-2022)
7.11. France HPV Vaccine Market: Growth and Forecast
7.11.1. France HPV Vaccine Market, By Value (2012-2016)
7.11.2. France HPV Vaccine Market, By Value (2017-2022)
7.12. France HPV Vaccine Market - By End-User, By Value
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)
7.13. Rest of Europe HPV Vaccine Market: Growth and Forecast
7.13.1. Rest of Europe HPV Vaccine Market, By Value (2012-2016)
7.13.2. Rest of Europe Vaccine Market, By Value (2017-2022)
8. ASIA-PACIFIC HPV VACCINE MARKET: GROWTH AND FORECAST
8.1. Asia-Pacific HPV Vaccine Market, By Value (2012-2016)
8.2. Asia-Pacific HPV Vaccine Market, By Value (2017-2022)
8.3. Asia-Pacific HPV Vaccine Market - By End-User, By Value
8.3.1. Asia-Pacific HPV Vaccine Market, By Value, % (2016)
8.3.2. Asia-Pacific HPV Vaccine Market, By Value, % (Forecast 2022F)
8.4. Asia-Pacific HPV Vaccine Market, By End-User, By Value (2012-2022)
8.4.1. Male, By Value (2012-2022)
8.4.2. Female, By Value (2012-2022)
8.5. Asia-Pacific HPV Vaccine Market, By Age-Group, By Value (2012-2022)
8.5.1. Adolescent, By Value (2012-2022)
8.5.2. Adult, By Value (2012-2022)
8.6. Asia-Pacific HPV Vaccine Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)
8.7. Japan HPV Vaccine Market: Growth and Forecast
8.7.1. Japan HPV Vaccine Market, By Value (2012-2016)
8.7.2. Japan HPV Vaccine Market, By Value (2017-2022)
8.8. Japan HPV Vaccine Market - By End-User, By Value
8.8.1. Male, By Value (2012-2022)
8.8.2. Female, By Value (2012-2022)
8.9. China HPV Vaccine Market: Growth and Forecast
8.9.1. China HPV Vaccine Market, By Value (2012-2016)
8.9.2. China HPV Vaccine Market, By Value (2017-2022)
8.10. China HPV Vaccine Market - By End-User, By Value
8.10.1. Male, By Value (2012-2022)
8.10.2. Female, By Value (2012-2022)
8.11. India HPV Vaccine Market: Growth and Forecast
8.11.1. India HPV Vaccine Market, By Value (2012-2016)
8.11.2. India HPV Vaccine Market, By Value (2017-2022)
8.12. India HPV Vaccine Market - By End-User, By Value
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)
9. ROW HPV VACCINE MARKET: GROWTH AND FORECAST
9.1. ROW HPV Vaccine Market, By Value (2012-2016)
9.2. ROW HPV Vaccine Market, By Value (2017-2022)
10. MARKET DYNAMICS
10.1. Increasing healthcare awareness about Sexually Transmissible Disease
10.2. Development of Healthcare Infrastructure
10.3. Rising global healthcare expenditure and favorable reimbursed policies
11. MARKET RESTRAINTS
12. MARKET TRENDS
13. SWOT ANALYSIS – HPV VACCINE MARKET
14. PORTER’S FIVE FORCES ANALYSIS
15. POLICY AND REGULATORY LANDSCAPE
16. COMPANY PROFILES
16.1. Merck and Co
16.2. GlaxoSmithKline
17. ABOUT US
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
4. HPV VACCINE MARKET: PRODUCT OUTLOOK
5. GLOBAL HPV VACCINE MARKET: GROWTH AND FORECAST
5.1. Global HPV Vaccine Market, By Value (2012-2016)
5.2. Global HPV Vaccine Market, By Value (2017-2022)
5.3. Global HPV Vaccine Market - By End-User, By Value
5.3.1. Global HPV Vaccine Market, By Value, % (2016)
5.3.2. Global HPV Vaccine Market, By Value, % (Forecast 2022F)
5.4. Global HPV Vaccine Market, By End-User, By Value (2012-2022)
5.4.1. Male, By Value (2012-2022)
5.4.2. Female, By Value (2012-2022)
5.5. Global HPV Vaccine Market, By Age-Group, By Value (2012-2022)
5.5.1. Adolescent, By Value (2012-2022)
5.5.2. Adult, By Value (2012-2022)
6. NORTH AMERICA HPV VACCINE MARKET: GROWTH AND FORECAST
6.1. North America HPV Vaccine Market, By Value (2012-2016)
6.2. North America HPV Vaccine Market, By Value (2017-2022)
6.3. North America HPV Vaccine Market - By End-User, By Value
6.3.1. North America HPV Vaccine Market, By Value, % (2016)
6.3.2. North America HPV Vaccine Market, By Value, % (Forecast 2022F)
6.4. North America HPV Vaccine Market, By End-User, By Value (2012-2022)
6.4.1. Male, By Value (2012-2022)
6.4.2. Female, By Value (2012-2022)
6.5. North America HPV Vaccine Market, By Age-Group, By Value (2012-2022)
6.5.1. Adolescent, By Value (2012-2022)
6.5.2. Adult, By Value (2012-2022)
6.6. North America HPV Vaccine Market: Country Analysis (U.S., Canada)
6.6.1. North America HPV Vaccine Market, Country Share, 2016 (% of Total)
6.6.2. North America HPV Vaccine Market, Country Share, 2022 (% of Total)
6.7. U.S. HPV Vaccine Market: Growth and Forecast
6.7.1. U.S. HPV Vaccine Market, By Value (2012-2016)
6.7.2. U.S. HPV Vaccine Market, By Value (2017-2022)
6.8. U.S. HPV Vaccine Market - By End-User, By Value
6.8.1. Male, By Value (2012-2022)
6.8.2. Female, By Value (2012-2022)
6.9. Canada HPV Vaccine Market: Growth and Forecast
6.9.1. Canada HPV Vaccine Market, By Value (2012-2016)
6.9.2. Canada HPV Vaccine Market, By Value (2017-2022)
6.10. Canada HPV Vaccine Market - By End-User, By Value
6.10.1. Male, By Value (2012-2022)
6.10.2. Female, By Value (2012-2022)
7. EUROPE HPV VACCINE MARKET: GROWTH AND FORECAST
7.1. Europe HPV Vaccine Market, By Value (2012-2016)
7.2. Europe HPV Vaccine Market, By Value (2017-2022)
7.3. Europe HPV Vaccine Market - By End-User, By Value
7.3.1. Europe HPV Vaccine Market, By Value, % (2016)
7.3.2. Europe HPV Vaccine Market, By Value, % (Forecast 2022F)
7.4. Europe HPV Vaccine Market, By End-User, By Value (2012-2022)
7.4.1. Male, By Value (2012-2022)
7.4.2. Female, By Value (2012-2022)
7.5. Europe HPV Vaccine Market, By Age-Group, By Value (2012-2022)
7.5.1. Adolescent, By Value (2012-2022)
7.5.2. Adult, By Value (2012-2022)
7.6. Europe HPV Vaccine Market: Country Analysis (U.K., Germany, France & Rest of Europe)
7.6.1. Europe HPV Vaccine Market, Country Share, 2016 (% of Total)
7.6.2. Europe HPV Vaccine Market, Country Share, 2022 (% of Total)
7.7. U.K. HPV Vaccine Market: Growth and Forecast
7.7.1. U.K. HPV Vaccine Market, By Value (2012-2016)
7.7.2. U.K. HPV Vaccine Market, By Value (2017-2022)
7.8. U.K. HPV Vaccine Market - By End-User, By Value
7.8.1. Male, By Value (2012-2022)
7.8.2. Female, By Value (2012-2022)
7.9. Germany HPV Vaccine Market: Growth and Forecast
7.9.1. Germany HPV Vaccine Market, By Value (2012-2016)
7.9.2. Germany HPV Vaccine Market, By Value (2017-2022)
7.10. Germany HPV Vaccine Market - By End-User, By Value
7.10.1. Male, By Value (2012-2022)
7.10.2. Female, By Value (2012-2022)
7.11. France HPV Vaccine Market: Growth and Forecast
7.11.1. France HPV Vaccine Market, By Value (2012-2016)
7.11.2. France HPV Vaccine Market, By Value (2017-2022)
7.12. France HPV Vaccine Market - By End-User, By Value
7.12.1. Male, By Value (2012-2022)
7.12.2. Female, By Value (2012-2022)
7.13. Rest of Europe HPV Vaccine Market: Growth and Forecast
7.13.1. Rest of Europe HPV Vaccine Market, By Value (2012-2016)
7.13.2. Rest of Europe Vaccine Market, By Value (2017-2022)
8. ASIA-PACIFIC HPV VACCINE MARKET: GROWTH AND FORECAST
8.1. Asia-Pacific HPV Vaccine Market, By Value (2012-2016)
8.2. Asia-Pacific HPV Vaccine Market, By Value (2017-2022)
8.3. Asia-Pacific HPV Vaccine Market - By End-User, By Value
8.3.1. Asia-Pacific HPV Vaccine Market, By Value, % (2016)
8.3.2. Asia-Pacific HPV Vaccine Market, By Value, % (Forecast 2022F)
8.4. Asia-Pacific HPV Vaccine Market, By End-User, By Value (2012-2022)
8.4.1. Male, By Value (2012-2022)
8.4.2. Female, By Value (2012-2022)
8.5. Asia-Pacific HPV Vaccine Market, By Age-Group, By Value (2012-2022)
8.5.1. Adolescent, By Value (2012-2022)
8.5.2. Adult, By Value (2012-2022)
8.6. Asia-Pacific HPV Vaccine Market: Country Analysis (Japan, China, India)
8.6.1. Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)
8.6.2. Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)
8.7. Japan HPV Vaccine Market: Growth and Forecast
8.7.1. Japan HPV Vaccine Market, By Value (2012-2016)
8.7.2. Japan HPV Vaccine Market, By Value (2017-2022)
8.8. Japan HPV Vaccine Market - By End-User, By Value
8.8.1. Male, By Value (2012-2022)
8.8.2. Female, By Value (2012-2022)
8.9. China HPV Vaccine Market: Growth and Forecast
8.9.1. China HPV Vaccine Market, By Value (2012-2016)
8.9.2. China HPV Vaccine Market, By Value (2017-2022)
8.10. China HPV Vaccine Market - By End-User, By Value
8.10.1. Male, By Value (2012-2022)
8.10.2. Female, By Value (2012-2022)
8.11. India HPV Vaccine Market: Growth and Forecast
8.11.1. India HPV Vaccine Market, By Value (2012-2016)
8.11.2. India HPV Vaccine Market, By Value (2017-2022)
8.12. India HPV Vaccine Market - By End-User, By Value
8.12.1. Male, By Value (2012-2022)
8.12.2. Female, By Value (2012-2022)
9. ROW HPV VACCINE MARKET: GROWTH AND FORECAST
9.1. ROW HPV Vaccine Market, By Value (2012-2016)
9.2. ROW HPV Vaccine Market, By Value (2017-2022)
10. MARKET DYNAMICS
10.1. Increasing healthcare awareness about Sexually Transmissible Disease
10.2. Development of Healthcare Infrastructure
10.3. Rising global healthcare expenditure and favorable reimbursed policies
11. MARKET RESTRAINTS
12. MARKET TRENDS
13. SWOT ANALYSIS – HPV VACCINE MARKET
14. PORTER’S FIVE FORCES ANALYSIS
15. POLICY AND REGULATORY LANDSCAPE
16. COMPANY PROFILES
16.1. Merck and Co
16.2. GlaxoSmithKline
17. ABOUT US
LIST OF FIGURES
Figure 1: Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 2: World Male Population Estimates, 2017 (In Millions)
Figure 3: World Female Population Estimates, 2017 (In Millions)
Figure 4: World Female Population, Age 10-14 Years Old (2012-2016)
Figure 5: World Male Population, Age 10-14 Years Old (2012-2016)
Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 7: Top 10 Most Frequent Cancer in Females, World, (Age-standardised incidence rate per 100,000 women)
Figure 8: Top 10 Most Frequent Cancer Deaths in Females, World, (Age-standardised incidence rate per 100,000 women)
Figure 9: Age-Standardized Cervical Cancer Incidence Rate (per 100,000 women per year), By Region
Figure 10: HPV Related Cancer Cases in Women/ Year, 530,000
Figure 11: HPV Related Cancer Cases in Men/ Year, 39,000
Figure 12: Global HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 13: Global HPV vaccine Market Size, By End-User, 2016 (%)
Figure 14: Global HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 15: Global HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 16: Global HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)
Figure 17: North America HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 18: North America GDP, 2012-2015 (USD Trillion)
Figure 19: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 20: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Figure 21: North America Female Population, Age 10-14 Years Old (2012-2016)
Figure 22: North America Male Population, Age 10-14 Years Old (2012-2016)
Figure 23: North America HPV Vaccine Market Size, By Value, 2017-2022(USD Million)
Figure 24: North America HPV vaccine Market Size, By End-User, 2016 (%)
Figure 25: North America HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 26: North America HPV Vaccine Market, End-User, By Value 2012-2022 (USD Million)
Figure 27: North America HPV Vaccine Market, By Age Group, By Value 2012-2022 (USD Million)
Figure 28: North America HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 29: North America HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 30: U.S. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 31: U.S. Female Population, Age 10-14 Years Old (2012-2016)
Figure 32: U.S. Male Population, Age 10-14 Years Old (2012-2016)
Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 34: U.S. HPV vaccine Market Size, By End-User, 2016 (%)
Figure 35: U.S. HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 36: U.S. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 37: Annual Sales of Cervarix vaccines in U.S., (In Million USD) 2012-2016
Figure 38: Canada HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 39: Canada Female Population, Age 10-14 Years Old (2012-2016)
Figure 40: Canada Male Population, Age 10-14 Years Old (2012-2016)
Figure 41: Normal Cytology
Figure 42: Low-Grade lesions
Figure 43: High-Grade lesions
Figure 44: Cervical Cancer
Figure 45: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 46: Canada HPV vaccine Market Size, By End-User, 2016 (%)
Figure 47: Canada HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 48: Canada HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 49: Europe HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 50: Europe, Female Population aged 15+, By Region, 2017 (In Millions)
Figure 51: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 52: Europe Female Population, Age 10-14 Years Old (2012-2016)
Figure 53: Europe Male Population, Age 10-14 Years Old (2012-2016)
Figure 54: Europe, GDP, By Select Country, 2016 (USD Billion)
Figure 55: Europe Health Spending Per Capita, By Select Country, 2016 (USD)
Figure 56: Europe HPV Vaccine Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 57: Europe HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 58: Europe HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 59: Europe HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 60: Europe HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)
Figure 61: Europe HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 62: Europe HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 63: Annual Sales of Cervarix vaccines in Europe, (In Million USD) 2012-2016
Figure 64: U.K. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 65: U.K. Female Population, Age 10-14 Years Old (2012-2016)
Figure 66: U.K. Male Population, Age 10-14 Years Old (2012-2016)
Figure 67: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 68: U.K., Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 69: U.K. HPV Vaccine Market Size, By End User, 2016 (%)
Figure 70: U.K. HPV Vaccine Market Size, By End User, 2022 (%)
Figure 71: U.K. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 72: Germany HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 73: Germany Female Population, Age 10-14 Years Old (2012-2016)
Figure 74: Germany Male Population, Age 10-14 Years Old (2012-2016)
Figure 75: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 76: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 77: Germany HPV Vaccine Market Size, By End User, 2016 (%)
Figure 78: Germany HPV Vaccine Market Size, By End User, 2022 (%)
Figure 79: Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 80: France HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 81: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 82: France Female Population, Age 10-14 Years Old (2012-2016)
Figure 83: France Male Population, Age 10-14 Years Old (2012-2016)
Figure 84: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 85: France HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 86: France HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 87: France HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 88: Rest of Europe HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 89: Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 90: Asia Female Population, Age 10-14 Years Old (2012-2016)
Figure 91: Asia Male Population, Age 10-14 Years Old (2012-2016)
Figure 92: APAC, GDP, By Select Country, 2016 (USD Billion)
Figure 93: APAC Health Expenditure Per Capita, Public and Private, By Select Country, 2016 (USD)
Figure 94: Asia-Pacific HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 95: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 96: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 97: Asia-pacific HPV Vaccine - End-User, By Value 2012-2022 (USD Million)
Figure 98: Asia-Pacific HPV Vaccine Market – Age Group, By Value 2012-2022 (USD Million)
Figure 99: Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 100: Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 101: Japan HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 102: Japan HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 103: Japan HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 104: Japan HPV Vaccine - End-User, By Value 2012-2022 (USD Million)
Figure 105: China HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 106: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 107: China Female Population, Age 10-14 Years Old (2012-2016)
Figure 108: China Male Population, Age 10-14 Years Old (2012-2016)
Figure 109: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 110: China HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 111: China HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 112: China HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)
Figure 113: India HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 114: India Female Population, Age 10-14 Years Old (2012-2016)
Figure 115: India Male Population, Age 10-14 Years Old (2012-2016)
Figure 116: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 117: India HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 118: India HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 119: India HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)
Figure 120: Rest of Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 121: ROW HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 122: ROW HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 123: Africa Female Population, Age 10-14 Years Old (2012-2016)
Figure 124: Africa Male Population, Age 10-14 Years Old (2012-2016)
Figure 125: Prevalence of Cervical Cancer, among women in Africa (Patients per 100,000 (2012-2016)
Figure 126: Prevalence of Cervical Cancer among female in Brazil (Patients per 100,000 (2012-2016)
Figure 127: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 128: Annual Sales of HPV vaccines, By leading players, (In Million USD) 2012-2016
Figure 129: Market Share of Leading players in HPV vaccine market, 2016
Figure 130: Merck & Co., Net Sales, 2012-2016 (In million USD)
Figure 131: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Figure 132: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Figure 133: Merck & Co., Net Revenue, By Business Segment, % Share 2016
Figure 134: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
Figure 135: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Figure 136: GlaxoSmithKline Sales, By Region, 2016 (%)
Figure 137: GlaxoSmithKline, Sales, By Segment 2016 (%)
Figure 1: Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 2: World Male Population Estimates, 2017 (In Millions)
Figure 3: World Female Population Estimates, 2017 (In Millions)
Figure 4: World Female Population, Age 10-14 Years Old (2012-2016)
Figure 5: World Male Population, Age 10-14 Years Old (2012-2016)
Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 7: Top 10 Most Frequent Cancer in Females, World, (Age-standardised incidence rate per 100,000 women)
Figure 8: Top 10 Most Frequent Cancer Deaths in Females, World, (Age-standardised incidence rate per 100,000 women)
Figure 9: Age-Standardized Cervical Cancer Incidence Rate (per 100,000 women per year), By Region
Figure 10: HPV Related Cancer Cases in Women/ Year, 530,000
Figure 11: HPV Related Cancer Cases in Men/ Year, 39,000
Figure 12: Global HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 13: Global HPV vaccine Market Size, By End-User, 2016 (%)
Figure 14: Global HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 15: Global HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 16: Global HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)
Figure 17: North America HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 18: North America GDP, 2012-2015 (USD Trillion)
Figure 19: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 20: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Figure 21: North America Female Population, Age 10-14 Years Old (2012-2016)
Figure 22: North America Male Population, Age 10-14 Years Old (2012-2016)
Figure 23: North America HPV Vaccine Market Size, By Value, 2017-2022(USD Million)
Figure 24: North America HPV vaccine Market Size, By End-User, 2016 (%)
Figure 25: North America HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 26: North America HPV Vaccine Market, End-User, By Value 2012-2022 (USD Million)
Figure 27: North America HPV Vaccine Market, By Age Group, By Value 2012-2022 (USD Million)
Figure 28: North America HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 29: North America HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 30: U.S. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 31: U.S. Female Population, Age 10-14 Years Old (2012-2016)
Figure 32: U.S. Male Population, Age 10-14 Years Old (2012-2016)
Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 34: U.S. HPV vaccine Market Size, By End-User, 2016 (%)
Figure 35: U.S. HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 36: U.S. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 37: Annual Sales of Cervarix vaccines in U.S., (In Million USD) 2012-2016
Figure 38: Canada HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 39: Canada Female Population, Age 10-14 Years Old (2012-2016)
Figure 40: Canada Male Population, Age 10-14 Years Old (2012-2016)
Figure 41: Normal Cytology
Figure 42: Low-Grade lesions
Figure 43: High-Grade lesions
Figure 44: Cervical Cancer
Figure 45: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 46: Canada HPV vaccine Market Size, By End-User, 2016 (%)
Figure 47: Canada HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 48: Canada HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 49: Europe HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 50: Europe, Female Population aged 15+, By Region, 2017 (In Millions)
Figure 51: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 52: Europe Female Population, Age 10-14 Years Old (2012-2016)
Figure 53: Europe Male Population, Age 10-14 Years Old (2012-2016)
Figure 54: Europe, GDP, By Select Country, 2016 (USD Billion)
Figure 55: Europe Health Spending Per Capita, By Select Country, 2016 (USD)
Figure 56: Europe HPV Vaccine Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 57: Europe HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 58: Europe HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 59: Europe HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 60: Europe HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)
Figure 61: Europe HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 62: Europe HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 63: Annual Sales of Cervarix vaccines in Europe, (In Million USD) 2012-2016
Figure 64: U.K. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 65: U.K. Female Population, Age 10-14 Years Old (2012-2016)
Figure 66: U.K. Male Population, Age 10-14 Years Old (2012-2016)
Figure 67: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 68: U.K., Per Capita Healthcare Expenditure, 2012-2016 (In USD)
Figure 69: U.K. HPV Vaccine Market Size, By End User, 2016 (%)
Figure 70: U.K. HPV Vaccine Market Size, By End User, 2022 (%)
Figure 71: U.K. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)
Figure 72: Germany HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 73: Germany Female Population, Age 10-14 Years Old (2012-2016)
Figure 74: Germany Male Population, Age 10-14 Years Old (2012-2016)
Figure 75: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 76: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 77: Germany HPV Vaccine Market Size, By End User, 2016 (%)
Figure 78: Germany HPV Vaccine Market Size, By End User, 2022 (%)
Figure 79: Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 80: France HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 81: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 82: France Female Population, Age 10-14 Years Old (2012-2016)
Figure 83: France Male Population, Age 10-14 Years Old (2012-2016)
Figure 84: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 85: France HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 86: France HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 87: France HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)
Figure 88: Rest of Europe HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 89: Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 90: Asia Female Population, Age 10-14 Years Old (2012-2016)
Figure 91: Asia Male Population, Age 10-14 Years Old (2012-2016)
Figure 92: APAC, GDP, By Select Country, 2016 (USD Billion)
Figure 93: APAC Health Expenditure Per Capita, Public and Private, By Select Country, 2016 (USD)
Figure 94: Asia-Pacific HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 95: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 96: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 97: Asia-pacific HPV Vaccine - End-User, By Value 2012-2022 (USD Million)
Figure 98: Asia-Pacific HPV Vaccine Market – Age Group, By Value 2012-2022 (USD Million)
Figure 99: Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)
Figure 100: Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)
Figure 101: Japan HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 102: Japan HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 103: Japan HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 104: Japan HPV Vaccine - End-User, By Value 2012-2022 (USD Million)
Figure 105: China HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 106: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 107: China Female Population, Age 10-14 Years Old (2012-2016)
Figure 108: China Male Population, Age 10-14 Years Old (2012-2016)
Figure 109: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 110: China HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 111: China HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 112: China HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)
Figure 113: India HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 114: India Female Population, Age 10-14 Years Old (2012-2016)
Figure 115: India Male Population, Age 10-14 Years Old (2012-2016)
Figure 116: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)
Figure 117: India HPV Vaccine Market Size, By End-User, 2016 (%)
Figure 118: India HPV Vaccine Market Size, By End-User, 2022 (%)
Figure 119: India HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)
Figure 120: Rest of Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)
Figure 121: ROW HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)
Figure 122: ROW HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)
Figure 123: Africa Female Population, Age 10-14 Years Old (2012-2016)
Figure 124: Africa Male Population, Age 10-14 Years Old (2012-2016)
Figure 125: Prevalence of Cervical Cancer, among women in Africa (Patients per 100,000 (2012-2016)
Figure 126: Prevalence of Cervical Cancer among female in Brazil (Patients per 100,000 (2012-2016)
Figure 127: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 128: Annual Sales of HPV vaccines, By leading players, (In Million USD) 2012-2016
Figure 129: Market Share of Leading players in HPV vaccine market, 2016
Figure 130: Merck & Co., Net Sales, 2012-2016 (In million USD)
Figure 131: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)
Figure 132: Merck & Co., Net Sales, By Geographic Location, % Share 2016
Figure 133: Merck & Co., Net Revenue, By Business Segment, % Share 2016
Figure 134: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)
Figure 135: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)
Figure 136: GlaxoSmithKline Sales, By Region, 2016 (%)
Figure 137: GlaxoSmithKline, Sales, By Segment 2016 (%)
LIST OF TABLES
Table A: Globally approved HPV vaccines, 2016
Table B: HPV Vaccine Market Segmentation Flowchart
Table C: Estimated number of HPV Associated cases in 2017
Table D: Estimated new HPV related cancers cases, 2011, 2012 & 2016
Table E: Newly registered diagnosed cases of HPV related cancer in England, 2016
Table F: Estimated and Predicted HPV related cancer among male and female, 2011, 2012 & 2016
Table G: Estimated and Predicted HPV related cancer among female, 2011, 2012 & 2016
Table H: Key Statistics on HPV burden in Asia
Table I: Estimated HPV related New Cancer Cases and Deaths (Thousands), By Sex, 2015
Table A: Globally approved HPV vaccines, 2016
Table B: HPV Vaccine Market Segmentation Flowchart
Table C: Estimated number of HPV Associated cases in 2017
Table D: Estimated new HPV related cancers cases, 2011, 2012 & 2016
Table E: Newly registered diagnosed cases of HPV related cancer in England, 2016
Table F: Estimated and Predicted HPV related cancer among male and female, 2011, 2012 & 2016
Table G: Estimated and Predicted HPV related cancer among female, 2011, 2012 & 2016
Table H: Key Statistics on HPV burden in Asia
Table I: Estimated HPV related New Cancer Cases and Deaths (Thousands), By Sex, 2015
